Study Title: Phase II Study of Consolidation Immunotherapy with Nivolumab and Ipilimumab or Nivolumab alone following Concurrent Chemoradiotherapy for Unresectable Stage IIIA/IIIB Non-small Cell Lung Cancer (NSCLC)
 

• Closed to Accrual at:
  • University of Illinois Cancer Center
  • Indiana University Melvin and Bren Simon Comprehensive Cancer Center
  • Michigan State University Breslin Cancer Center
  • Masonic Cancer Center, University of Minnesota
  • Penn State Cancer Institute
  • Rutgers Cancer Institute of New Jersey
  • Fred & Pamela Buffett Cancer Center (University of Nebraska)
  • University of Wisconsin Carbone Cancer Center
  • Barbara Ann Karmanos Cancer Center
  • Rush University Cancer Center
  • Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
  • University of Louisville James Graham Brown Cancer Center
• Learn more:
  • clinicaltrials.gov: NCT03285321
  • Big Ten CRC News Release
• Publications and Presentations:
  • Poster Discussion: 2020 ASCO Annual Meeting
  • Poster Session: 2019 ASCO Annual Meeting
  • Trials in Progress Poster Session: 2018 ASCO-SITC Clinical Immuno-Oncology Symposium

Study Contact: studies@hoosiercancer.org; (317) 921-2050.